Health Catalyst Debt to Equity Ratio 2018-2025 | HCAT
Current and historical debt to equity ratio values for Health Catalyst (HCAT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Health Catalyst debt/equity for the three months ending September 30, 2025 was 0.46.
| Health Catalyst Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-09-30 | $0.26B | $0.33B | 0.77 |
| 2025-06-30 | $0.27B | $0.35B | 0.77 |
| 2025-03-31 | $0.52B | $0.38B | 1.37 |
| 2024-12-31 | $0.49B | $0.37B | 1.35 |
| 2024-09-30 | $0.46B | $0.36B | 1.29 |
| 2024-06-30 | $0.34B | $0.36B | 0.94 |
| 2024-03-31 | $0.34B | $0.36B | 0.95 |
| 2023-12-31 | $0.34B | $0.37B | 0.91 |
| 2023-09-30 | $0.33B | $0.38B | 0.86 |
| 2023-06-30 | $0.33B | $0.39B | 0.85 |
| 2023-03-31 | $0.35B | $0.41B | 0.86 |
| 2022-12-31 | $0.33B | $0.43B | 0.77 |
| 2022-09-30 | $0.34B | $0.44B | 0.76 |
| 2022-06-30 | $0.34B | $0.47B | 0.73 |
| 2022-03-31 | $0.34B | $0.48B | 0.72 |
| 2021-12-31 | $0.31B | $0.52B | 0.59 |
| 2021-09-30 | $0.30B | $0.55B | 0.54 |
| 2021-06-30 | $0.29B | $0.28B | 1.04 |
| 2021-03-31 | $0.30B | $0.27B | 1.13 |
| 2020-12-31 | $0.30B | $0.28B | 1.09 |
| 2020-09-30 | $0.27B | $0.30B | 0.91 |
| 2020-06-30 | $0.23B | $0.23B | 0.99 |
| 2020-03-31 | $0.11B | $0.20B | 0.51 |
| 2019-12-31 | $0.10B | $0.20B | 0.51 |
| 2019-09-30 | $0.11B | $0.21B | 0.55 |
| 2019-06-30 | $0.00B | $0.00B | 0.00 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | $0.00B | 0.00 |
| 2017-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.167B | $0.307B |
| Health Catalyst Inc. is a provider of data and analytics technology and services to healthcare organizations. Health Catalyst Inc. is based in Salt Lake City, Utah. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $37.032B | 42.83 |
| Tempus AI (TEM) | United States | $12.162B | 0.00 |
| Doximity (DOCS) | United States | $7.681B | 31.63 |
| Hims & Hers Health (HIMS) | United States | $6.948B | 56.52 |
| IRhythm Holdings (IRTC) | United States | $5.309B | 0.00 |
| Hinge Health (HNGE) | United States | $3.288B | 0.00 |
| Privia Health (PRVA) | United States | $2.947B | 184.31 |
| 10x Genomics (TXG) | United States | $2.935B | 0.00 |
| Heartflow (HTFL) | United States | $2.853B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.348B | 38.85 |
| Omnicell (OMCL) | United States | $2.303B | 47.08 |
| Azenta (AZTA) | United States | $1.886B | 77.38 |
| Clover Health Investments (CLOV) | United States | $1.385B | 0.00 |
| Enovis (ENOV) | United States | $1.347B | 7.07 |
| Schrodinger (SDGR) | United States | $1.277B | 0.00 |
| Butterfly Network (BFLY) | United States | $1.187B | 0.00 |
| Phreesia (PHR) | United States | $0.953B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.871B | 0.00 |
| Talkspace (TALK) | United States | $0.658B | 132.33 |
| Standard BioTools (LAB) | United States | $0.619B | 0.00 |
| Claritev (CTEV) | United States | $0.497B | 0.00 |
| Evolent Health (EVH) | United States | $0.429B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.373B | 0.00 |
| Carlsmed (CARL) | United States | $0.352B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.326B | 0.00 |
| TruBridge (TBRG) | United States | $0.311B | 14.31 |
| Senseonics Holdings (SENS) | United States | $0.307B | 0.00 |
| CapsoVision (CV) | United States | $0.293B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.263B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.196B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.191B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.163B | 0.00 |
| CareCloud (CCLD) | United States | $0.130B | 7.12 |
| Outset Medical (OM) | United States | $0.098B | 0.00 |
| American Well (AMWL) | United States | $0.081B | 0.00 |
| Pulmonx (LUNG) | United States | $0.079B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.071B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.067B | 0.00 |
| HeartBeam (BEAT) | United States | $0.064B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.060B | 0.00 |
| 111 (YI) | China | $0.046B | 0.00 |
| Precipio (PRPO) | United States | $0.043B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.035B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.019B | 0.00 |
| Zhongchao (ZCMD) | China | $0.012B | 0.00 |
| HeartSciences (HSCS) | United States | $0.011B | 0.00 |
| PROFUSA (PFSA) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |